Compass Pathways Q1 Net Income $91.2M; FDA Rolling NDA & CNPV Awarded
COMPASS Pathways plc reported Q1 2026 financial results, highlighting significant regulatory progress for its COMP360 psilocybin therapy. The FDA granted a rolling NDA submission and review request, and a Commissioner’s National Priority Review Voucher (CNPV) was awarded, potentially accelerating the review timeline. The company achieved a net income of $91.2 million for the quarter, a substantial improvement from a net loss of $17.9 million in the prior year, largely due to a non-cash gain on warrant fair value adjustment. With a strong cash position of $466.0 million, the company expects its cash runway to extend into 2028, supporting its goal to be launch-ready by year-end and complete the final NDA submission for COMP360 in Q4 2026.
Key Highlights
- FDA granted rolling NDA submission and review for COMP360 based on Phase 3 data.
- Commissioner's National Priority Review Voucher (CNPV) awarded for COMP360, potentially accelerating review.
- Cash and cash equivalents were $466.0 million as of March 31, 2026, up from $149.6 million at Dec 31, 2025.
- Q1 2026 net income was $91.2 million, compared to a $17.9 million net loss in Q1 2025.
- Research and development expenses decreased to $26.5 million in Q1 2026 from $30.9 million in Q1 2025.
- General and administrative expenses decreased to $16.4 million in Q1 2026 from $18.7 million in Q1 2025.
- Final NDA submission for COMP360 is on track for Q4 2026.
- Current cash position is expected to fund operating expenses and capital expenditure requirements into 2028.